1. Home
  2. BELFA vs AGIO Comparison

BELFA vs AGIO Comparison

Compare BELFA & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bel Fuse Inc.

BELFA

Bel Fuse Inc.

HOLD

Current Price

$245.50

Market Cap

2.3B

Sector

N/A

ML Signal

HOLD

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

HOLD

Current Price

$25.73

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BELFA
AGIO
Founded
1949
2007
Country
United States
United States
Employees
4964
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
2.0B
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
BELFA
AGIO
Price
$245.50
$25.73
Analyst Decision
Strong Buy
Buy
Analyst Count
4
8
Target Price
$174.25
$38.88
AVG Volume (30 Days)
76.5K
1.3M
Earning Date
04-29-2026
04-29-2026
Dividend Yield
0.10%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$43,011,000.00
Revenue This Year
$9.74
$76.75
Revenue Next Year
$6.34
$170.73
P/E Ratio
$40.02
N/A
Revenue Growth
N/A
N/A
52 Week Low
$60.97
$22.24
52 Week High
$242.28
$46.00

Technical Indicators

Market Signals
Indicator
BELFA
AGIO
Relative Strength Index (RSI) 73.32 32.24
Support Level $114.22 $24.16
Resistance Level N/A $29.69
Average True Range (ATR) 8.34 1.27
MACD 3.42 -1.09
Stochastic Oscillator 91.49 0.48

Price Performance

Historical Comparison
BELFA
AGIO

About BELFA Bel Fuse Inc.

Bel Fuse Inc designs and manufactures electronic components that protect and connect electronic circuits. Its product portfolio is divided into three categories: magnetic solutions, power solutions & protection, and connectivity solutions. These products are used for the computer, networking, telecommunications, transportation and defense/aerospace, automotive, medical, and consumer electronics industries. Its geographical segments are the United States, Macao, United Kingdom, Slovakia, Germany, Switzerland, and All other foreign countries. Majority of the revenue is derived from United States.

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.

Share on Social Networks: